Enzyme replacement therapy and fatigue in adults with Pompe disease

Molecular Genetics and Metabolism

Volumn 109, Issue 2, 2013, Pages 174-178

  Güngör, Deniz ^a   De Vries, Juna M ^a   Brusse, Esther ^a   Kruijshaar, Michelle E ^a   Hop, Wim C J ^a   Murawska, Magda ^a   Van den Berg, Linda E M ^a   Reuser, Arnold J J ^a   Van Doorn, Pieter A ^a   Hagemans, Marloes L C ^a   Plug, Iris ^a   Van der Ploeg, Ans T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alglucosidase alfa; Enzyme replacement therapy; Fatigue; Lysosomal storage disorders; Pompe disease

Indexed keywords

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; DEPRESSION; DISEASE DURATION; ENZYME REPLACEMENT; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; FORCED VITAL CAPACITY; GLYCOGEN STORAGE DISEASE TYPE 2; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL SCALE; MUSCLE STRENGTH; PRIORITY JOURNAL; RATING SCALE; WHEELCHAIR;

ADULT; AGED; ALPHA-GLUCOSIDASES; ENZYME REPLACEMENT THERAPY; FATIGUE; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 84878493460     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.03.016     Document Type: Article

References (33)

1. de Vries J.M., Hagemans M.L., Bussmann J.B., van der Ploeg A.T., van Doorn P.A. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol. Life Sci. 2010, 67:701-713.
2. Chaudhuri A., Behan P.O. Fatigue in neurological disorders. Lancet 2004, 363:978-988.
3. Hagemans M.L., Winkel L.P., Van Doorn P.A., Hop W.J., Loonen M.C., Reuser A.J., Van der Ploeg A.T. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005, 128:671-677.
4. van den Berg L.E., de Vries J.M., Verdijk R.M., van der Ploeg A.T., Reuser A.J., van Doorn P.A. A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers. Neuromuscul. Disord. 2011, 21:232-234.
5. Hagemans M.L., van Schie S.P., Janssens A.C., van Doorn P.A., Reuser A.J., van der Ploeg A.T. Fatigue: an important feature of late-onset Pompe disease. J. Neurol. 2007, 254:941-945.
6. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet 2008, 372:1342-1353.
7. Engel A., Hirschhorn R., Huie M.L. Acid maltase deficiency. Myology 2004, McGraw-Hill, New York. A. Engel, C. Franzini-Armstrong (Eds.).
8. Mellies U., Stehling F., Dohna-Schwake C., Ragette R., Teschler H., Voit T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 2005, 64:1465-1467.
9. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N. Engl. J. Med. 2010, 362:1396-1406.
10. Angelini C., Semplicini C., Ravaglia S., Bembi B., Servidei S., Pegoraro E., Moggio M., Filosto M., Sette E., Crescimanno G., Tonin P., Parini R., Morandi L., Marrosu G., Greco G., Musumeci O., Di Iorio G., Siciliano G., Donati M.A., Carubbi F., Ermani M., Mongini T., Toscano A., Italian G.G. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years. J. Neurol. 2012, 259:952-958.
11. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Muller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
12. Bembi B., Pisa F.E., Confalonieri M., Ciana G., Fiumara A., Parini R., Rigoldi M., Moglia A., Costa A., Carlucci A., Danesino C., Pittis M.G., Dardis A., Ravaglia S. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J. Inherit. Metab. Dis. 2010, 33:727-735.
13. Toscano A., Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J. Neurol. 2013, 260:951-959.
14. van Capelle C.I., Winkel L.P., Hagemans M.L., Shapira S.K., Arts W.F., van Doorn P.A., Hop W.C., Reuser A.J., van der Ploeg A.T. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul. Disord. 2008, 18:447-452.
15. Papadimas G.K., Spengos K., Konstantinopoulou A., Vassilopoulou S., Vontzalidis A., Papadopoulos C., Michelakakis H., Manta P. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Clin. Neurol. Neurosurg. 2011, 113:303-307.
16. Orlikowski D., Pellegrini N., Prigent H., Laforet P., Carlier R., Carlier P., Eymard B., Lofaso F., Annane D. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul. Disord. 2011, 21:477-482.
17. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46:1121-1123.
18. Merkies I.S., Schmitz P.I., Samijn J.P., van der Meche F.G., van Doorn P.A. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999, 53:1648-1654.
19. Dittner A.J., Wessely S.C., Brown R.G. The assessment of fatigue: a practical guide for clinicians and researchers. J. Psychosom. Res. 2004, 56:157-170.
20. Garssen M.P., Van Koningsveld R., Van Doorn P.A. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. J. Neurol. 2006, 253:1143-1146.
21. van der Beek N.A., van Capelle C.I., van der Velden-van Etten K.I., Hop W.C., van den Berg B., Reuser A.J., van Doorn P.A., van der Ploeg A.T., Stam H. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol. Genet. Metab. 2011, 104:129-136.
22. Medical Research Council Aids to Examination of the Peripheral Nervous System 1976, Her Majesty's Stationary Office, London.
23. de Vries J.M., van der Beek N.A., Hop W.C., Karstens F.P., Wokke J.H., de Visser M., van Engelen B.G., Kuks J.B., van der Kooi A.J., Notermans N.C., Faber C.G., Verschuuren J.J., Kruijshaar M.E., Reuser A.J., van Doorn P.A., van der Ploeg A.T. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J. Rare Dis. 2012, 7:73.
24. Zigmond Snaith The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 361-370.
25. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 2002, 52:69-77.
26. Preisler N., Laforet P., Madsen K.L., Hansen R.S., Lukacs Z., Orngreen M.C., Lacour A., Vissing J. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Mol. Genet. Metab. 2012, 107:462-468.
27. McArdle W. Skeletal muscle: structure and function. Exercise Physiology 1996, 314-336. Williams and Wilkins, Baltimore. D. Balado (Ed.).
28. Strober L.B., Arnett P.A. An examination of four models predicting fatigue in multiple sclerosis. Arch. Clin. Neuropsychol. 2005, 20:631-646.
29. Skapinakis P., Lewis G., Mavreas V. Temporal relations between unexplained fatigue and depression: longitudinal data from an international study in primary care. Psychosom. Med. 2004, 66:330-335.
30. Brusse E., Brusse-Keizer M.G., Duivenvoorden H.J., van Swieten J.C. Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom. Neurology 2011, 76:953-959.
31. Siegert R.J., Abernethy D.A. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2005, 76:469-475.
32. Garssen M.P., Schmitz P.I., Merkies I.S., Jacobs B.C., van der Meche F.G., van Doorn P.A. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J. Neurol. Neurosurg. Psychiatry 2006, 77:61-65.
33. Bussmann J.B., Garssen M.P., van Doorn P.A., Stam H.J. Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J. Rehabil. Med. 2007, 39:121-125.